In vivo BRAF-mutant melanoma models with fluorescent markers to track stage-specific changes in macrophages under targeted therapy with BRAFi/MEKi, showed a rise in CCR2+ macrophage infiltration at the onset of a drug-tolerant persister (DTP) state after several weeks of treatment [127]. The gene discussed is CCR2; the disease is melanoma.